Abstract
Purpose :
Current literature has explored risk factors and varying clinical presentations for central serous chorioretinopathy (CSCR) in the general population. However, there is little research on the features of CSCR in the veteran population. The purpose of this retrospective observational study is to determine the epidemiology and clinical characteristics of CSCR in the veteran population.
Methods :
Patients with ICD-9 (362.41) and ICD-10 (H35.711, H35.712, H35.713 and H35.719) diagnostic codes for CSCR between 2011-2021 were queried and compiled. Patient variables evaluated include gender, length of disease, classification of disease (acute, persistent, recurrent), and presentation of disease. Descriptive statistical analysis was done with chi-squared test, multivariate logistic regressions, and student t-tests using Python (V 3.9.12).
Results :
A total of 173 patients were included in the final study population. Of the study population, 34 (19.7%) were classified as acute, 119 (68.8%) were classified as persistent, and 39 (22.5%) were classified as recurrent CSCR (Figure 1). Bilateral presentation of acute, persistent, and recurrent groups was 35.30%, 30.30%, and 28.20%, respectively. 169 patients (97.7%) were male, and 4 patients (2.3%) were female. The average length of disease was 44.5 [95% CI: 35.71-53.23] months for males and 87.3 [95% CI: 0->100] months for females. Acute, persistent, and recurrent CSCR patients had an average disease length of 3.8 months [95% CI: 2.73-4.96, p-value <0.001], 60.7 months [95% CI: 49.63-71.82, p-value <0.001], and 22.9 months [95% CI: 8.69-37.17, p-value <0.001], respectively (Figure 2). There was a total of 64 recurrent episodes among recurrent CSCR patients, an average of 2.06 recurrent episodes per patient.
Conclusions :
Among all three subtypes of CSCR, chronically affected veterans were the most common subtype of CSCR found and had the longest average length of disease duration. Our study suggests a difference in presentation of CSCR among the veteran population, though further research on the clinical characteristics and efficacy of treatment in veterans is needed.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.